Tagged with Artificial Intelligence

Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…

Global Five conferences, five continents’ worth of anxiety, one unmistakable pattern: the global pharma industry is being reshaped faster than it can keep up. From Philadelphia to Geneva, Istanbul to Chicago to London, the Shawview Consulting team found the same threads running through every panel and corridor conversation — AI and…

USA Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to realise AstraZeneca’s bold ambition to eliminate cancer as a cause of death and shares how this mission goes beyond developing…

Japan We have evolved well beyond the traditional CRO model Global biopharma companies are looking at Japan through a different lens, seeking partners that can navigate an increasingly complex regulatory landscape while supporting integrated development across Asia. At the heart of that evolution is CMIC, whose President and Representative Executive Officer,…

USA As precision medicine forces biopharma to rethink how it builds, runs, and scales laboratory and manufacturing infrastructure, the industry’s next competitive advantage will be found not in discovery, but in operational execution. Few are better positioned to make that argument than Michael Stubblefield, recently appointed CEO of PerkinElmer, who is…

USA You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of commercialisation reshape the pharmaceutical industry, Deborah Glasser reflects on how Sanofi is positioning its specialty care business for the next…

Global Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as Capria Ventures’ Francis Perelman outlines, a new wave of AI-native startups is building for precisely those conditions, deploying tools that…

APAC Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s shift into a global clinical development hub, the rise of Greater China as a leading source of innovation, with mainland…

China China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded across the entire value chain: drug discovery, clinical trial management, medical imaging, patient triage, and hospital workflows. Insilico Medicine is…

UAE Prof. Fatma Al Jasmi, Professor of Biochemical Genetics at the UAE University’s College of Medicine & Health Science and the UAE’s first biochemical genetics consultant, has spent nearly two decades building a rare and genetic disease infrastructure from the ground up. Prof. Al Jasmi traces that journey – from persuading…

UAE H.E. Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, sets out the emirate’s ambition to build the world’s most integrated and intelligent healthcare system. Drawing on the Emirati Genome Programme, a pioneering newborn and premarital screening infrastructure, and a rapidly expanding life sciences ecosystem,…

Taiwan Joe Yeh describes founding aetherAI to digitise pathology and embed AI into routine diagnostics, addressing inefficiency, subjectivity, and missed disease detection. He explains Taiwan’s rapid adoption, a research-driven market access strategy, flexible pricing, and global expansion across Germany, Japan, and the US, positioning AI-driven pathology as foundational infrastructure for precision…